Regarding subtypes, high AR1 expression was more frequent in HER2-positive (62.0%, 93/150) and luminal tumours (65.0%, 104/160) whereas high AR1 expression was almost absent in triple-negative tumours (4.3%, 3/69) (p < 0.0001). Here, TCF20 is linked to neoplasm.